Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
2018 Recommendations of the International Antiviral Society–USA Panel

Michael S. Saag, MD; Constance A. Benson, MD; Rajesh T. Gandhi, MD; Jennifer F. Hoy, MBBS; Raphael J. Landovitz, MD; Michael J. Mugavero, MD, MHSc; Paul E. Sax, MD; Davey M. Smith, MD; Melanie A. Thompson, MD; Susan P. Buchbinder, MD; Carlos del Rio, MD; Joseph J. Eron Jr, MD; Gerd Fätkenheuer, MD; Huldrych F. Günthard, MD; Jean-Michel Molina, MD; Donna M. Jacobsen, BS; Paul A. Volberding, MD

**IMPORTANCE**  Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection.

**OBJECTIVE**  To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for individuals at risk.

**EVIDENCE REVIEW**  New evidence collected since the International Antiviral Society–USA 2016 recommendations via monthly PubMed and EMBASE literature searches up to April 2018; data presented at peer-reviewed scientific conferences. A volunteer panel of experts in HIV research and patient care considered these data and updated previous recommendations.

**FINDINGS**  ART is recommended for virtually all HIV-infected individuals, as soon as possible after HIV diagnosis. Immediate initiation (eg, rapid start), if clinically appropriate, requires adequate staffing, specialized services, and careful selection of medical therapy. An integrase strand transfer inhibitor (INSTI) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) is generally recommended for initial therapy, with unique patient circumstances (eg, concomitant diseases and conditions, potential for pregnancy, cost) guiding the treatment choice. CD4 cell count, HIV RNA level, genotype, and other laboratory tests for general health and co-infections are recommended at specified points before and during ART. If a regimen switch is indicated, treatment history, tolerability, adherence, and drug resistance history should first be assessed; 2 or 3 active drugs are recommended for a new regimen. HIV testing is recommended at least once for anyone who has ever been sexually active and more often for individuals at ongoing risk for infection. Preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and appropriate monitoring is recommended for individuals at risk for HIV.

**CONCLUSIONS AND RELEVANCE**  Advances in HIV prevention and treatment with antiretroviral drugs continue to improve clinical management and outcomes for individuals at risk for and living with HIV.
ew drugs and new approaches to prevent and manage HIV infection necessitate an update to the International Antiretroviral (formerly AIDS) Society–USA (IAS-USA) recommendations, last published in 2016. This report incorporates current data on new regimens and new approaches into recommendations for the treatment and prevention of HIV.

Methods

Recommendations were developed by an international panel of 16 volunteer experts in HIV research and care. Members were screened for expertise, involvement in research and care, financial relationships, and ability to work toward consensus (ie, ability to consider all available data, evidence, and group discussions or opinions to reach agreement on recommendations). The panel convened in person (N = 2) and by conference calls (N = 10 full-panel and multiple subgroup calls) from September 2017 to June 2018. Teams for each section evaluated relevant evidence and drafted recommendations for full-panel review.

New evidence used was published in the literature, presented at major conferences, or released as safety reports. Monthly literature searches were conducted in PubMed and EMBASE between July 2016 and April 2018. Approximately 237 relevant citations were identified from more than 4490 reports. Abstracts presented at scientific conferences since July 2016 were identified. Relevant scientific publications or abstracts presented at peer-reviewed conferences were requested from drug manufacturers.

These updated recommendations focus on adults (≥18 years) with or at risk for HIV infection in settings in which most antiretroviral drugs are available or in late-stage development (new drug application filed). Recommendations were made by consensus and rated according to strength of the recommendation and quality of the evidence (Table 1). For recommendations that have not changed substantially or for which few new data have become available since 2016, the prior report should be reviewed. Details about the development process, panel, evidence collection and literature searches, and sponsor (IAS-USA) and its policies are reported in the Supplement.

When to Start

Recommendations for initiating antiretroviral therapy (ART) are summarized in Box 1. In patients with established HIV, ART should be initiated as soon as possible after diagnosis. The question of when to start ART is focused now on whether immediate ART (same day to 14 days after diagnosis) is preferred. The World Health Organization endorsed ART initiation within 7 days of new diagnosis (including same day), citing improved viral suppression. Rapid initiation of ART requires improving linkage to care and addressing structural barriers (eg, staffing and services availability) within clinics and ART distribution systems.

Rapid ART Start

Randomized trials in Lesotho, Haiti, and South Africa showed significant improvements in viral load suppression at 10 or 12 months and retention in care with rapid initiation of therapy. In 1 study, individuals were randomized to early ART with simplified counseling and point-of-care CD4 cell assays or to standard care. In the intervention group, 80% began ART within 14 days and 71% started ART the same day of eligibility, compared with 38% and 18%, respectively, in the control group. Virologic suppression at 1 year was improved in the intervention group (85% vs 75%).

Several cohorts examined the feasibility, outcomes, and challenges of rapid ART start. Meta-analyses of 8 cohorts showed an improvement in the proportion of patients starting ART within 3 months but no benefit on retention in care. A statistically non-significant trend toward worse viral suppression was observed for those who started ART rapidly in 1 cohort. San Francisco implemented a citywide rapid ART program in which newly diagnosed persons were linked to care within 5 days from diagnosis and offered treatment on the day of their clinic visit. Of 265 newly diagnosed persons, 97% were linked to care (30% within 5 days) and 81% started ART; time from diagnosis to HIV RNA level below 200 copies/mL decreased by more than 50% and time from first care visit to ART decreased from 27 days to 1 day. A large HIV clinic in Atlanta implemented rapid access to ART on the day of the initial visit. Median time from initial diagnosis to HIV RNA level below 200 copies/mL decreased from 67 to 41 days; however, the program was not sustainable because of increased patient load and inadequate funding for staffing.

Despite the success of rapid ART initiation in some settings, starting ART on the day of diagnosis requires coordination between testing and treatment settings and access to resources that may limit treatment uptake. All elements of conventional treatment initiation must be in place at the treatment site but provided in a way that ensures immediate access.

ART initiation, including rapid start, is recommended for all infected ambulatory patients committed to starting ART (unless the patient has symptoms that suggest an opportunistic infection for which immediate ART is contraindicated) or for those with unclear HIV diagnosis (eg, discordant serologic or rapid test results) (evidence rating AII). Because of concerns about transmitted drug resistance (eg, K103N mutation), immediate ART should not be nonnucleoside reverse transcriptase inhibitor (NNRTI)-based (evidence rating AII). Dolutegravir/tenofovir alafenamide (TAF) (or tenofovir disoproxil fumarate [TDF])/emtricitabine (or lamivudine) or bictegravir/TAF/emtricitabine or boosted darunavir TAF (or TDF)/emtricitabine (or lamivudine) are recommended for rapid initiation (AII). Patients requiring abacavir should not begin until the result of testing for the HLA-B*5701 allele is available (evidence rating AIA).

When to Start ART in the Setting of Active Opportunistic Infections and Malignancies

Recommendations for initiating ART in the setting of active opportunistic infections (OIs) remain unchanged. ART should be started within the first 2 weeks after diagnosis for most OIs (evidence rating AIA). Data further support the recommendation to start ART within the first 2 weeks of initiation of tuberculosis treatment for patients with CD4 cell counts below 50/μL and within the first 2 to 8 weeks for those with CD4 cell counts of 50/μL and above (evidence rating AIA). For patients with cryptococcal meningitis in high-resourced settings with access to optimal antifungal therapy, frequent monitoring, and aggressive management of intracranial
pressure, ART should begin within 2 weeks of diagnosis.\textsuperscript{14,15} Careful monitoring for immune reconstitution inflammatory syndrome is essential. For individuals diagnosed with HIV and a malignancy concurrently, ART should be initiated immediately.\textsuperscript{1} Early adverse effects of ART can be monitored and managed while cancer staging and molecular testing are performed.

**Primary OI Prophylaxis**

With ART universally recommended, the incidence of *Pneumocystis* pneumonia and major AIDS-associated OIs has declined to less than 1.45 and 0.4 per 100 person-years, respectively, in the United States.\textsuperscript{16} For individuals with viral suppression while taking ART, the incidence and overall mortality of *Mycobacterium avium* complex disease is sufficiently low\textsuperscript{17,18} that primary *Mycobacterium avium* complex prophylaxis is no longer recommended (evidence rating Alia). Primary prophylaxis for *Pneumocystis* pneumonia is still recommended for patients meeting CD4 criteria (evidence rating Alia).\textsuperscript{17,19} Primary prophylaxis for cryptococcal disease is not recommended in settings where incidence is low (evidence rating Allia).

**Recommended Initial Regimens**

Recommendations for initial ART are summarized in **Box 2**. Regimens that do not require boosting with ritonavir or cobicistat are favored. Choosing a combination with a high barrier to resistance is important, particularly for individuals with inconsistent adherence. As more generic ART medications become available, cost and access to medications are likely to be of increasing importance (see below). Regimens are also listed for patients who cannot take the generally recommended initial regimens owing to anticipated problems with adherence, drug interactions, patient preference, financial considerations, or lack of availability of recommended options.

Recommended initial ART for most patients is listed in alphabetic order by integrase strand transfer inhibitor (InSTI) component (see also **Table 2** for medications and their associated advantages and disadvantages). Bictegravir and dolutegravir do not require pharmacologic boosting, have a high barrier to resistance, and are part of regimens with a low pill burden and toxicity. Studies of these drugs in initial regimens have shown comparable efficacy and no emergence of resistant virus.\textsuperscript{20,21} There are substantially more data and longer-term experience with dolutegravir (approved in the United States in 2013) than with bictegravir (approved in 2018). Preliminary data have raised concerns regarding use of dolutegravir (and potentially other InSTIs) for individuals capable of becoming pregnant (see below). Raltegravir is well tolerated and has fewer drug interactions than other InSTIs but has a lower barrier to resistance and a higher pill burden. Elvitegravir regimens also have a lower barrier to resistance and include a pharmacologic booster (cobicistat) that results in more drug interactions.

In combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs), the NNRTIs efavirenz and rilpivirine each demonstrate high rates of virologic suppression as initial therapy. Efavirenz-based treatment was standard initial therapy for many years, but studies have demonstrated higher rates of adverse effects (rash and central nervous system adverse effects) than InSTI-based therapy. Rilpivirine has a lower rate of central nervous system adverse effects and rash than efavirenz and is coformulated with TAF/emtricitabine into the smallest single tablet for initial therapy. However, rilpivirine must be taken with food, requires stomach acidity
for adequate absorption, and is recommended only for patients with baseline HIV RNA level below 100,000 copies/mL and CD4 cell count above 200/μL.

The NNRTI doravirine is currently under investigation for initial therapy. In phase 3 trials, doravirine was noninferior to efavirenz and to ritonavir-boosted darunavir in achieving virologic suppression and had fewer central nervous system adverse events than efavirenz and a better lipid profile than either efavirenz or ritonavir-boosted darunavir.22,23 Thus, doravirine may be preferable to existing NNRTIs, but no prospective studies compare it with InSTI-based regimens. Non-InSTI initial regimens are summarized in Table 3.

Abacavir is a component of the recommended regimen dolutegravir/abacavir/lamivudine. Individuals who test positive for the HLA-B*5701 allele are at risk of a potentially life-threatening hypersensitivity reaction to abacavir.24 Results of HLA-B*5701 testing must be available before use (evidence rating A); patients who test positive should not be given abacavir (evidence rating A), and this information should be documented in the medical record.

Although some prior comparisons of abacavir/lamivudine and TDF/emtricitabine demonstrated an efficacy advantage of TDF/emtricitabine in patients with high HIV-1 RNA levels,25 the differences have not been observed in studies that use InSTIs.26 Abacavir has no activity against hepatitis B virus (HBV) and should not be used in patients with HIV and HBV.

TAF- and TDF-containing regimens are similar virologically. Compared with TDF, TAF results in a lower plasma level of tenofovir and higher intracellular concentration of the active antiviral component tenofovir diphosphate. This results in fewer tenofovir-associated renal and bone toxic effects.27 These differences between TAF and TDF are accentuated when TDF is used with ritonavir or cobicitabistat, which increase tenofovir plasma levels.28

### Two-Drug Initial Therapy

Initial 2-drug regimens are under investigation. This strategy may offer cost or toxicity advantages over standard 3-drug regimens, but efficacy needs to be confirmed.27 Darunavir/ritonavir plus raltegravir was noninferior to darunavir/ritonavir plus 2 NRTIs, but the 2-drug regimen had higher rates of treatment failure in patients with a CD4 cell count below 200/μL or an HIV RNA level above 100,000 copies/mL.28

Dolutegravir plus lamivudine and darunavir/ritonavir plus lamivudine are being studied.29,30 Until further data are available, initial 2-drug regimens are reserved for the rare situation when individuals cannot take abacavir, TAF, or TDF. In this situation, darunavir/ritonavir plus raltegravir (if <100,000 HIV RNA copies/mL and CD4 cell count >200/μL) or darunavir/ritonavir plus lamivudine may be used (if there is no lamivudine resistance) (evidence rating B); Short-term data from comparative trials may provide support for dolutegravir plus lamivudine as initial 2-drug therapy (NCT02831764). Dolutegravir plus rilpivirine has not yet been assessed for initial therapy.31

### Unique Considerations

#### Pregnancy

Individuals who are pregnant should initiate ART as soon as possible for their own health and to reduce transmission to the infant (evidence rating A). The NRTI options include abacavir/lamivudine (or emtricitabine) if patient tests negative for HLA-B*5701 or TDF/emtricitabine (or lamivudine). Insufficient safety data for TAF preclude use of this drug during pregnancy.

A preliminary report revealed neural tube defects among infants born to women taking a dolutegravir-containing regimen at conception, suggesting, for now, that dolutegravir should be avoided in individuals of childbearing age who wish to become pregnant, are trying to get pregnant, or are sexually active and not reliably using
contraception. All individuals of childbearing age should have documentation of a negative pregnancy test result before starting dolutegravir and should be counseled regarding this potential risk. More data are expected; it is not yet clear whether other InSTIs pose a similar risk of neural tube defects.

Raltegravir is the recommended InSTI for individuals who are already pregnant. Elvitegravir/cobicistat should not be used during pregnancy (evidence rating AIIa). Pregnant women already taking elvitegravir/cobicistat should be switched to a recommended regimen. Bictegravir should not be used during pregnancy because available safety data are insufficient.

Recommended protease inhibitors (PIs) include atazanavir/ritonavir (once daily) or darunavir/ritonavir (twice daily). Drugs boosted with cobicistat (eg, darunavir/cobicistat and atazanavir/ cobicistat) are not recommended for use during pregnancy because of pharmacokinetic concerns or insufficient data (evidence rating AIIb). Efavirenz and rilpivirine are alternatives in pregnancy. There were initial concerns regarding potential neural tube defects with efavirenz, but accumulated data now support the safety of efavirenz during pregnancy.

**HBV and Hepatitis C Virus Co-infection**

HIV-infected patients with HBV co-infection should initiate an ART regimen that contains TDF or TDF (evidence rating AIIa). Lamivudine or emtricitabine, and a third component. Patients with HIV co-infected with hepatitis C virus (HCV) are candidates for HCV treatment and therefore should start an ART regimen with drugs that have minimal drug interactions with HCV therapies (evidence rating AIIa), such as dolutegravir/abacavir/lamivudine, dolutegravir/TAF/emtricitabine, bictegravir/TAF/emtricitabine, or raltegravir plus TAF/emtricitabine. Clinicians should consult current HCV treatment guidelines (https://www.hcvguidelines.org).

**Bone, Kidney, and Cardiovascular Disease**

HIV is associated with osteoporosis and fractures. Baseline bone mineral density testing is recommended in postmenopausal women and in anyone older than 50 years (evidence rating BIII). During the first 1 to 2 years after ART initiation, patients may lose 2% to 6% of bone mineral density at the hip and spine. Patients taking TDF-containing regimens have a greater initial decline in bone mineral density than those who take a TAF- or abacavir-containing regimen. Accordingly, TDF is not recommended for patients with osteopenia or osteoporosis (evidence rating BIII). Abacavir does not require dose adjustment based on renal function. TAF can be used if creatinine clearance is above 30 mL/min/1.73 m² (evidence rating AIIa). Dose reduction of lamivudine is recommended for patients with creatinine clearance below 50 mL/min/1.73 m². There are data supporting use of elvitegravir/cobicistat/TAF/emtricitabine once daily in patients with end-stage renal disease (estimated glomerular filtration rate <15 mL/min) receiving long-term hemodialysis. HIV-infected patients with end-stage renal disease should be evaluated for kidney transplantation (evidence rating AIIa).

---

**Table 2. Advantages and Disadvantages of Currently Available Integrase Strand Transfer Inhibitors**

<table>
<thead>
<tr>
<th>Drug*</th>
<th>Year of FDA Approval</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bictegravir 2018</td>
<td>Coformulated with TAF/emtricitabine as part of a complete initial regimen</td>
<td>Noninferior to dolutegravir in comparative trials</td>
<td>Requires pharmacokinetic boosting with cobicistat for once-daily dosing</td>
</tr>
<tr>
<td></td>
<td>Once-daily dosing</td>
<td>Low risk of resistance with virologic failure</td>
<td>Lower barrier to resistance than bictegravir and dolutegravir</td>
</tr>
<tr>
<td></td>
<td>Relatively few drug interactions</td>
<td>Raising serum creatinine levels (≈0.1 mg/dL) through inhibition of tubular secretion of creatinine</td>
<td>Frequent drug interactions attributable to cobicistat boosting</td>
</tr>
<tr>
<td></td>
<td>Can be taken with or without food</td>
<td>Should be taken with food</td>
<td>Should be avoided in pregnant women because of inadequate plasma levels</td>
</tr>
<tr>
<td></td>
<td>Can be started without HLA-B*5701 testing</td>
<td>Concerns regarding neural tube defects in infants born to women who conceived while taking dolutegravir; unknown whether this is a class effect (see text)</td>
<td>Concerns regarding neural tube defects in infants born to women who conceived while taking dolutegravir; unknown whether this is a class effect (see text)</td>
</tr>
<tr>
<td>Dolotegravir 2013</td>
<td>Noninferior to bictegravir in 2 comparative trials and superior to darunavir and efavirenz in comparative trials</td>
<td>Noninferior to dolutegravir in a comparative clinical trial</td>
<td>Not coformulated as part of a complete regimen</td>
</tr>
<tr>
<td></td>
<td>Once-daily dosing</td>
<td>Superior to raltegravir in treatment-experienced patients</td>
<td>Lower barrier to resistance than bictegravir or dolutegravir</td>
</tr>
<tr>
<td></td>
<td>Available as a single agent, allowing it to be used in other combinations</td>
<td>Can be taken with or without food</td>
<td>Higher pill burden than with other InSTIs</td>
</tr>
<tr>
<td></td>
<td>Low risk of resistance with virologic failure</td>
<td>Can be taken with or without food</td>
<td>Concerns regarding neural tube defects in infants born to women who conceived while taking dolutegravir; unknown whether this is a class effect (see text)</td>
</tr>
<tr>
<td></td>
<td>Relatively few drug interactions</td>
<td>Can be taken with or without food</td>
<td>Low risk of resistance with virologic failure</td>
</tr>
<tr>
<td>Elvitegravir 2012</td>
<td>Once-daily dosing</td>
<td>Coformulated with TDF/emtricitabine or TAF/emtricitabine as a complete regimen</td>
<td>Requires pharmacokinetic boosting with cobicistat for once-daily dosing</td>
</tr>
<tr>
<td></td>
<td>Coformulated with TDF/emtricitabine or TAF/emtricitabine as a complete regimen</td>
<td>Coformulated with TDF/emtricitabine or TAF/emtricitabine as a complete regimen</td>
<td>Lower barrier to resistance than bictegravir and dolutegravir</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Frequent drug interactions attributable to cobicistat boosting</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Raising serum creatinine levels (0.1-0.15 mg/dL) through inhibition of tubular secretion of creatinine</td>
</tr>
<tr>
<td>Raltegravir 2007</td>
<td>Once-daily dosing</td>
<td>Superior to raltegravir-boosted atazanavir and ritonavir-boosted darunavir in a comparative clinical trial</td>
<td>Superior to raltegravir-boosted atazanavir and ritonavir-boosted darunavir in a comparative clinical trial</td>
</tr>
<tr>
<td></td>
<td>Longest safety record</td>
<td>Longest safety record</td>
<td>Lower barrier to resistance than bictegravir or dolutegravir</td>
</tr>
<tr>
<td></td>
<td>Fewest drug interactions</td>
<td>Fewest drug interactions</td>
<td>Higher pill burden than with other InSTIs</td>
</tr>
<tr>
<td></td>
<td>Can be taken with or without food</td>
<td>Can be taken with or without food</td>
<td>Concerns regarding neural tube defects in infants born to women who conceived while taking dolutegravir; unknown whether this is a class effect (see text)</td>
</tr>
</tbody>
</table>

Abbreviations: FDA, US Food and Drug Administration; InSTI, integrase strand transfer inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. S| conversion factor: To convert creatinine values to μmol/L, multiply by 88.4

* In alphabetic order. The use of abacavir and TAF or TDF is described in the text.
The association between abacavir use and increased risk of myocardial infarction remains controversial.\(^4\)\(^5\) Given the uncertainty, abacavir should be used with caution or avoided in patients who have or are at high risk for cardiovascular disease.

### Recommended Initial ART in the Setting of OIs and Malignancies

Choice of ART regimen in the setting of OIs and malignancies is guided by drug-drug interactions with the antimicrobial or chemotherapy regimen. Unboosted InSTI-based regimens are recommended. In the setting of malignancy, OI prophylaxis should be instituted, regardless of CD4 cell count, according to specific chemotherapy regimens used.

The recommended regimens for initial ART in the setting of rifamycin-based antituberculosis therapy are 2 NRTIs (excluding TAF) plus efavirenz (600 mg daily), raltegravir (800 mg twice daily), or dolutegravir (50 mg twice daily) (evidence rating A).\(^1\)\(^4\) Coadministration of bictegravir (along with TAF/emtricitabine) twice daily with rifampin for 28 days is not recommended, owing to significantly decreased area under the curve (AUC) and peak serum concentration after administration (C\(_{max}\)) for bictegravir (evidence rating A).\(^2\) When TAF is administered with rifampin, plasma TAF C\(_{max}\) and AUC as well as intracellular tenofovir diphosphate levels were decreased; however, intracellular tenofovir diphosphate concentrations were higher than those achieved with standard-dose TDF. Further evaluation of TAF in tuberculosis coinfection is under way.\(^4\)\(^3\) Boosted PIs should be used only if an efavirenz- or InSTI-based regimen is not an option, and rifabutin (150 mg daily) should be substituted for rifampin in the antituberculosis regimen (evidence rating A).\(^1\)

For latent tuberculosis, a 1-month course of daily rifapentine plus isoniazid was equivalent to 9 months of isoniazid in persons with HIV.\(^4\)\(^4\) Daily rifapentine can be safely administered with efavirenz-based ART. Once-weekly rifapentine/isoniazid is also safe, well-tolerated, and has an acceptable pharmacokinetic profile when used with raltegravir. Dolutegravir-based regimens should not be used with rifapentine/isoniazid for treatment or prevention of tuberculosis, pending further evaluation.\(^4\)\(^5\)

### When and How to Switch

Recommendations for when and how to switch ART regimens are summarized in Box 3. The most common reasons for switching therapy are regimen simplification, newly diagnosed comorbidities (or to prevent comorbid conditions), and management of interactions with drugs or supplements. In addition to these reasons, a regimen switch may be required to minimize the patient’s insurance co-payments or to satisfy payer formulary requirements.

Switching from older antiretroviral regimens should be considered when there is evidence of or potential for chronic toxicity, drug-drug interactions, or emergent adverse effects with current regimens.\(^1\)\(^3\)\(^1\)\(^6\)\(^6\) Proactive switching from TDF- to TAF-containing regimens to minimize renal or bone adverse effects may be beneficial.\(^4\)\(^7\) Care should be taken when switching from regimens boosted with ritonavir to ones boosted with cobicistat because of different drug-drug interactions.\(^4\)\(^8\)

In patients without a history of treatment failure, data support switching from regimens containing TDF to single-tablet regimens including dolutegravir/abacavir/lamivudine,\(^4\)\(^6\)\(^4\) dolutegravir/rilpivirine,\(^3\)\(^7\) elvitegravir/cobicistat/emtricitabine/TAF,\(^1\) rilpivirine/emtricitabine/TAF,\(^5\)\(^0\) darunavir/cobicistat/emtricitabine/TAF,\(^3\)\(^8\) and bictegravir/emtricitabine/TAF.\(^2\)\(^0\) The switch to TAF-containing regimens is effective in maintaining HIV and HBV suppression in HIV/HBV co-infection.\(^5\)\(^2\)

### Table 3. Initial Non-InSTI Antiretroviral Treatments\(^a\)\(^b\)\(^c\)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darunavir (boosted with cobicistat or ritonavir) plus TAF/emtricitabine or TDF/emtricitabine</td>
<td>Low risk of resistance with virologic failure, even with intermittent adherence</td>
<td>Requires pharmacokinetic boosting; many drug interactions</td>
</tr>
<tr>
<td>Efavirenz/TDF/emtricitabine</td>
<td>High efficacy in patients with baseline HIV RNA levels &gt;100 000 copies/mL</td>
<td>Relatively high rate of rash</td>
</tr>
<tr>
<td>Rilpivirine/TAF (or TDF)/emtricitabine</td>
<td>Lowest risk of rash among NRTI-based therapies</td>
<td>Not recommended for patients with HIV RNA levels &gt;100 000 copies/mL or CD4 cell count &lt;200/μL because of increased risk of virologic failure</td>
</tr>
</tbody>
</table>

Abbreviations: InSTI, integrase strand transfer inhibitor; NRTI, nonnucleoside reverse transcriptase inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

\(^a\) In alphabetic order by first component. Initial NRTI-based regimens should not be used without baseline resistance data because of the possible presence of transmitted NRTI-resistant virus. In the rare circumstance in which maraviroc might be included in initial therapy, initiation should not occur before confirmation of CC chemokine receptor 5 tropism.

\(^b\) Of note, doravirine, an investigational NRTI, is currently under regulatory review. If approved, doravirine/lamivudine/TDF would likely be an effective initial regimen in patients for whom use of an InSTI-containing regimen is not possible.

\(^c\) See text with regard to interchanging TDF for TAF and interchanging emtricitabine for lamivudine and vice versa.
Simplification from a boosted PI53 or from emtricitabine/TAF plus dolutegravir54 to a single-tablet bictegravir/emtricitabine/TAF regimen maintained virologic suppression above 90%. Switching to 2 antiretroviral drugs has been used to reduce NRTI-related bone, kidney, and cardiovascular complications and cost. Dolutegravir/raltegravir maintained virologic suppression in patients with no previous virologic failure or evidence of resistance who switched from a 3-drug ART regimen.31 Dual-therapy regimens that include a boosted PI (lopinavir, atazanavir, or darunavir) and lamivudine were noninferior to 3-drug regimens in maintaining virologic suppression up to 2 years.55-57 Dolutegravir and lamivudine maintained virologic suppression to 48 weeks among patients with no prior virologic failure or transmitted NRTI resistance.58,59 Fewer options exist for regimen simplification in virologically suppressed individuals in whom several previous regimens have failed over time. Preexistent NRTI and NNRTI mutations were associated with viral rebound after switching to rilpivirine/emtricitabine/TDF.60 Darunavir/cobicistat/emtricitabine/TAF maintained virologic suppression in patients switching from a boosted PI plus emtricitabine/TDF, even if there was previous virologic failure, provided there was no history of darunavir failure or darunavir-resistance mutations.51 Elvitegravir/cobicistat/emtricitabine/TAF combined with darunavir taken once daily effectively maintained virologic suppression in patients with 2-class drug resistance (up to 3 thymidine analogue-associated mutations but no multi-NRTI or darunavir mutations) while taking multidrug regimens.63 Monotherapy with PIs or InSTIs as a maintenance strategy is not recommended because of higher rates of virologic rebound,1,62-65 often with resistant virus (evidence rating AIIb).62,63

Virologic Failure

Virologic failure is increasingly uncommon with currently recommended ART regimens. Exploration for reasons of inconsistent adherence, drug-drug interactions, and collation of all resistance mutations identified by genotype, along with the ART history, are required to select a new treatment regimen.

For failure of an initial NNRTI-based regimen, dolutegravir plus NRTIs was superior to lopinavir plus NRTIs when the next regimen included at least 1 active NRTI.66 For failure of initial PI-based or InSTI-based therapy (without resistance), boosted PI- or dolutegravir-based therapy with 1 or 2 fully active NRTIs should be effective.

For virologic failure after initial raltegravir- or elvitegravir-based regimens with the presence of integrase mutations, dolutegravir (50 mg twice daily) with at least 1 other active drug may be effective, but clinical data are lacking.1 For virologic failure with more complex treatment history, therapy with at least 2 fully active drugs from

Box 3. Selected Recommendations for When and How to Switch ART Regimens

- Review of the ART treatment history, regimen tolerability, comediations, and results of prior resistance tests is recommended before any treatment switches are made (evidence rating AIIa).
- In patients with NRTI mutations, switching from a boosted PI to a regimen containing a drug with a low genetic barrier to resistance (eg, NNRTI or raltegravir) is not recommended (evidence rating AIIa).
- HIV viral load should be checked 1 month after switching regimens to ensure virologic suppression has been maintained (evidence rating BII).

Switching When Virologically Suppressed

- Patients taking older ART drugs with known toxicity should be questioned carefully to identify subtle adverse effects of which they may be unaware or that they may not attribute to the drug. The presence of these toxicities should prompt a change in regimen (evidence rating BII).
- In general, if the older regimen is well tolerated without evidence of toxicity, there is little reason to switch to a newer regimen (evidence rating BII).
- Proactive switching from TDF to TAF is recommended for patients at high risk of renal or bone toxicity (evidence rating BII). Review of comediations is essential to ensure no change in dosing is required with the use of TAF.
- Switching from 3-drug regimens to certain 2-drug regimens in the setting of viral suppression, using dolutegravir/rilpivirine (evidence rating AIIa), a boosted PI with lamivudine (evidence rating AIIa), or dolutegravir with lamivudine (evidence rating BII) can be used in patients with no prior virologic failure or transmitted drug resistance. (Longer-term follow-up is needed to confirm the durability of these strategies).
- Patients who are co-infected with HIV and HBV should receive a regimen that contains 2 drugs active against HBV, usually TAF or TDF plus lamivudine or emtricitabine, in addition to a third ART drug (evidence rating AIIa). Such patients should generally not be switched to 2-drug ART.
- Monotherapy with boosted PIs or dolutegravir is not recommended (evidence rating AIIa).

Switching for Virologic Failure

- Resistance testing is recommended while taking the failing ART regimen or within 4 weeks of stopping (evidence rating AIIa).
- Virologic failure should be confirmed and, if resistance is identified, a prompt switch to another active regimen using results of current and past resistance testing to prevent accumulation of additional resistance mutations is recommended (evidence rating BIIa).
- Dolutegravir, plus 2 NRTIs (with at least 1 active by genotype) is recommended after initial treatment failure with an NNRTI (evidence rating AIIa).
- A boosted PI plus 2 NRTIs (with at least 1 active NRTI) are recommended for initial treatment failure of an InSTI-containing regimen (evidence rating AIIa).
- Dolutegravir plus at least 1 fully active other agent may be effective in the setting of raltegravir or elvitegravir resistance. Dolutegravir should be dosed twice daily in this setting (evidence rating BII).
- A single active agent added to a failing regimen is not recommended (evidence rating AIIa).
- For multiclass resistance, the next regimen should be constructed using drugs from new classes if available (evidence rating BII).

Abbreviations: ART, antiretroviral therapy; HBV, hepatitis B virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

© 2018 American Medical Association. All rights reserved.
different antiretroviral classes, perhaps including maraviroc in the setting of CC chemokine receptor 5 (CCR5)-tropic virus, is recommended.

Ibalizumab, an anti-CD4 monoclonal antibody that inhibits HIV cell entry via CD4 binding, is active against CCR5- and C-X-C chemokine receptor 4 (CXCR4)-tropic HIV isolates and may be useful as a fully active agent for patients with multiclass-resistant virus (evidence rating BII). Almost 50% of adults with virologic failure from multidrug-resistant HIV achieved undetectable HIV RNA levels at 24 weeks after receipt of biweekly intravenous ibalizumab (800 mg) with at least 1 other active drug.67,68

Laboratory Monitoring

Recommendations for laboratory monitoring are summarized in Table 4 and Box 4. All individuals who have ever been sexually active should be tested for HIV at least once in their lives (evidence rating AII). Risk for HIV often changes over a person’s lifetime; risk evaluation is recommended at each routine clinical visit (evidence rating AII). For men who have sex with men (MSM), transgender women, people who inject drugs, and others with increased risk, testing should be assessed, along with HIV RNA level. HIV RNA suppression (evidencerating BIII).1,84 Afterward, CD4 cell counts are recommended every 6 months if the patient maintains consistent medication adherence (evidencerating BIII).85 CD4 measurements are recommended every 6 months until virus is suppressed.1,83 CD4 cell counts are recommended every 3 months (evidencerating BIII).78-81 Testing for CCR5 tropism is recommended each time when considering maraviroc, and HLA-B*5701 testing (only needed once) is recommended before starting abacavir (evidence rating AII).

Monitoring During ART

Within 6 weeks of starting ART, adherence and tolerability of therapy should be assessed, along with HIV RNA level. HIV RNA suppression may take up to 24 weeks, or faster with InSTI-based regimens.1,82 Once the HIV RNA level is below 50 copies/mL, monitoring is recommended every 3 months until suppressed for at least 1 year. After that year, monitoring can be performed every 6 months if the patient maintains consistent medication adherence (evidencerating AII). Of note, when monitoring intervals are extended and therapy fails, resistance has more time to emerge.86

Once viral suppression occurs with ART, CD4 cell counts usually increase.1,83 CD4 measurements are recommended every 6 months until above 250/μL for at least 1 year with concomitant virologic suppression (evidencerating BIII).1,84 Afterward, CD4 cell counts need not be measured unless ART fails (defined below) or the patient has an immunosuppressive condition or treatment, such as steroid treatments or chemotherapy (evidencerating AII).85 Patients taking ART should have regular clinical and laboratory evaluations, including age- and risk-appropriate screening.

HIV RNA testing is used to detect if ART is failing. When HIV RNA level is above 50 copies/mL, repeating measurement of HIV RNA
Engagement in Care and ART Adherence

Recommendations for engagement in care and ART adherence are summarized in Box 5. The HIV care continuum provides a framework to enhance individual health outcomes and maximize the benefits afforded by treatment as prevention. In the setting of sustained viral suppression, individuals with HIV do not transmit HIV to sexual partners (described as “undetectable = untransmissible” [U = U]). In the United States, 22% of initial HIV diagnoses occur within 3 months of an AIDS diagnosis, indicating that persons are entering HIV care late. Clinicians not offering HIV testing in emergency departments and acute medical care settings appears to be a major limitation in early diagnosis of HIV.

Optimal care for patients with persistent viremia between 50 and 200 copies/mL is unclear. The ART regimen should be continued, with assessment of medication adherence (evidence rating BII). There is no indication to intensify the regimen with additional antiretrovirals.

Box 4. Selected Recommendations for Laboratory Monitoring

All persons who have ever been sexually active should be tested for HIV at least once in their lives (evidence rating AII). Risk for HIV often changes over a person’s lifetime; risk evaluation is recommended at each routine clinical visit (evidence rating AII).

For sexually active men who have sex with men and for transgender women, people who inject drugs, and others at increased risk, testing is recommended at least annually and as frequently as every 3 months (evidence rating BII).

Diagnosis of sexually transmitted infections and hepatitis C virus can help identify persons who should be tested more regularly for HIV and who might benefit from preexposure prophylaxis (evidence rating BII).

HIV screening with assays that can detect recent HIV infection, either an instrument-based combination antigen/antibody assay or a combination of a stand-alone antibody assay and nucleic acid testing, is recommended (evidence rating AII).

Persons with ongoing condomless sexual exposures or sharing of needles or works need to be tested with assays that can detect HIV RNA or with combination antibody + p24 antigen tests (evidence rating AII). Individuals with signs or symptoms of acute or primary HIV infection should be tested with HIV RNA assays.

All available tests can have false-positive results, so additional testing with an HIV viral load is recommended before ART initiation, although treatment may be started before results are available (evidence rating AII).

HIV genotype to assess transmitted NRTI and NNRTI resistance should be performed; InSTI genotyping at baseline is not recommended unless exposure to a partner with InSTI resistance is suspected (evidence rating BII).

CCR5 tropism testing is recommended each time when considering maraviroc and HLA-B*5701 testing (only needed once) before use of abacavir (evidence rating AII).

Once HIV RNA level is below 50 copies/mL, monitoring is recommended every 3 months until virus is suppressed for at least a year. After 1 year of viral suppression, monitoring can be reduced to every 6 months if the patient maintains consistent medication adherence (evidence rating AII).

Measurement of CD4 cell counts is recommended every 6 months until cell counts are above 250/µL for at least 1 year with concomitant viral suppression (evidence rating BII).

Age- and risk-appropriate screening for STIs at various anatomical sites, anal or cervical dysplasia, tuberculosis, general health, and medication toxicity is recommended (evidence rating AII).

Once a viral load above 50 copies/mL is detected, measurement should be repeated within 4 weeks, and reassessing for medication adherence and tolerability is recommended (evidence rating AII).

Measurement of viral load at 4 to 6 weeks after starting a new ART regimen is recommended (evidence rating BII).

If the viral load has not declined, adherence and toxicity should be discussed with the patient. If adherence appears to be sufficient, a genotype assay is recommended (evidence rating BII).

Abbreviations: ART, antiretroviral therapy; CRCS, CC chemokine receptor 5; InSTI, integrate strand transfer inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; STI, sexually transmitted infection.
with poor medication adherence, visit retention, and clinical outcomes. Chronic depression increases the risk for missed clinic visits, virologic failure, and a 2-fold increase in mortality risk. Treatment with antidepressants can improve virologic suppression, CD4 cell counts, and remission from clinical symptoms.

### Cost

From the patient perspective, the most relevant cost is the out-of-pocket expense of accessing treatment. The payer perspective is to use the lowest-cost medications to avoid the most expensive and severe HIV outcomes (eg, hospitalizations). The latter perspective often places greater value on immediate costs rather than prevention of events occurring remotely in time (eg, renal or cardiovascular toxicity). For example, a patient and clinician might value the renal and bone safety of TAF over that of TDF, but the payer might determine that the similar virologic efficacy does not justify the higher cost of TAF.

The societal perspective considers the cost and outcomes for all parties involved. Since this perspective does not favor one group over another, it is adopted by most cost-effectiveness analyses for which therapies are considered in relation to each other, with the one providing the greatest return on investment being preferred. For example, despite its high cost, the benefits of ART are so large it is considered cost-effective.

The availability of more generic antiretrovirals and the use of 2-drug regimens could reduce the costs of treatment substantially. Generic antiretrovirals have already reduced the cost of HIV treatment globally, allowing millions of patients to be treated in resource-limited settings. In developed countries, many antiretroviral agents and coformulations are available as lower-cost generics. Limitations include a forced switch from branded coformulated regimens to separate pills, more pharmacy co-pays for separate prescriptions; use of older agents that are not part of current recommended regimens; and high costs if an insufficient number of generic manufacturers enter the market. However, a modeling study found that use of a partially generic regimen including multiple pills would be highly cost-effective.

Ultimately, the first priority for clinicians and patients is to find the most effective and safest treatment. If multiple options exist with similar outcomes, choosing the lowest-cost options makes intuitive sense, provided there are no additional patient cost barriers.

### Prevention

Recommendations for the prevention of HIV infection are summarized in Box 6. Use of antiretrovirals for HIV prevention spans 3 domains: treatment as prevention, prophylaxis for currently uninfected individuals (PrEP and postexposure prophylaxis [PEP]), and prevention of mother-to-child transmission.

As noted, maintaining U = U status requires continued viral suppression. There are 2 caveats to consider when counseling patients about U = U: The only transmissions that occurred in studies happened early after starting treatment and 3 to 6 months of viral suppression may therefore be required; and durable viral suppression cannot be assessed based on a single measurement. Importantly, transmission

---

### Box 5. Selected Recommendations for Engagement in Care and ART Adherence

<table>
<thead>
<tr>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine, opt-out HIV screening is recommended in primary medical care settings, emergency departments, and for all pregnant women (evidence rating AIIa).</td>
</tr>
<tr>
<td>Routine screening and treatment for depression is recommended (evidence rating AIIa).</td>
</tr>
<tr>
<td>Systematic monitoring of time to care linkage after initial HIV diagnosis, retention in care, reengagement in care, ART adherence, and rates of viral suppression is recommended in all care settings and at a population level (evidence rating AIIa).</td>
</tr>
<tr>
<td>Brief, strengths-based case management is recommended after HIV diagnosis to facilitate linkage to care (evidence rating AIIa).</td>
</tr>
<tr>
<td>Systematic monitoring of missed clinic visits and rapid intervention after a missed visit is recommended (evidence rating AIIa).</td>
</tr>
<tr>
<td>Personal telephone and interactive text reminders in advance of scheduled appointments and shortly after missed appointments (eg, 24-48 hours) are recommended (evidence rating AIIa).</td>
</tr>
<tr>
<td>Adherence monitoring using patients’ self-report obtained by validated adherence instruments and pharmacy refill data is recommended (evidence rating AIIa).</td>
</tr>
<tr>
<td>Integration of directly observed ART in methadone maintenance programs (evidence rating Bla) and as a treatment strategy among persons with substance use disorders (evidence rating Bla) and those who are incarcerated or released to the community (evidence rating CII) is recommended to enhance adherence and viral suppression.</td>
</tr>
<tr>
<td>Opioid substitution therapy for opioid-dependent patients is recommended (evidence rating AIIa).</td>
</tr>
<tr>
<td>Rapid HIV test algorithms may be used to confirm a preliminary positive rapid test result, allowing for same-day referral to treatment from nonclinical settings (evidence rating AIIa).</td>
</tr>
<tr>
<td>Use of public health surveillance in conjunction with clinic-level data to guide individual-level linkage and reengagement in care activities is recommended (evidence rating Bla).</td>
</tr>
<tr>
<td>Cash financial incentives for clinic appointment attendance and achievement of viral suppression are generally not recommended as a retention-in-care strategy (evidence rating AIIa).</td>
</tr>
<tr>
<td>Data-driven risk stratification to identify high-acuity, high-need patients for combination intervention strategies to improve care engagement and viral suppression is recommended (evidence rating CIIb).</td>
</tr>
<tr>
<td>Screening for and addressing housing instability, food insecurity, ongoing substance use, psychiatric disorders, medication adverse effects, and pill burden is recommended (evidence rating Bla).</td>
</tr>
</tbody>
</table>

Abbreviation: ART, antiretroviral therapy.
Box 6. Selected Recommendations for Prevention of HIV Infection

HIV-seropositive and -negative individuals should be reminded that condoms are required to prevent acquisition of non-HIV STIs (evidence rating AIIa). Quarterly screening for asymptomatic STIs is recommended for all populations with high rates of bacterial STIs and incomplete condom use (evidence rating Alia).

Abacavir-based PrEP is not recommended unless the exposed patient is known to be negative for the HLA-B*5701 allele (evidence rating AlII). PrEP is recommended for populations whose annual HIV incidence is at least 2% (evidence rating AlII).

Daily TDF/emtricitabine is the recommended regimen for men and women (evidence rating Alia) and transgender individuals (evidence rating Alia) at risk of sexual exposure (evidence rating Alia) and people who inject drugs (evidence rating Blia). A 1-week lead-in time is recommended with daily dosing for rectal, penile, and vaginal exposures with daily TDF/emtricitabine to ensure adequate tissue levels are achieved (evidence rating Clia). At PrEP discontinuation, TDF/emtricitabine should continue for 1 week after the last sexual exposure (evidence rating Clia).

For individuals with active HBV infection (detectable HBsAg), discontinuation of TDF/emtricitabine PrEP could lead to acute HBV flares or hepatic decompensation, particularly for patients with hepatic cirrhosis; careful monitoring of HBV infection and liver function is recommended after discontinuation of TDF/emtricitabine (evidence rating Alia).

Percutaneous TDF/emtricitabine PrEP, also known as on-demand, event-driven, or “2-1-1” dosing may be considered as an alternative to daily PrEP for MSM with infrequent sexual exposures (evidence rating Alia). This regimen is not recommended in other risk groups or in patients with active HBV infection because of the risk of hepatitis flare and hepatic decompensation (evidence rating Blia). If intercourse is planned in the context of 2-1-1 PrEP regimen, the first (double) dose of TDF/emtricitabine should be taken closer to the 24-hour precoital time than the 2-hour time (evidence rating Clia).

TDF/lamivudine, TAF/emtricitabine, and TDF alone are not recommended for PrEP (evidence rating BIIa). TDF-based PrEP is not recommended in persons with creatinine clearance below 60 mL/min/1.73 m² (evidence rating Alia).

HIV testing, preferably with a combination antigen-antibody assay (evidence rating AlII), to confirm HIV-seronegative status is mandatory at time of initiation of TDF/emtricitabine PrEP; HIV RNA testing should be obtained if acute HIV is suspected.

Measurement of serum creatinine level, determination of estimated glomerular filtration rate, and HBsAg testing are recommended before initiation of PrEP but need not impede PrEP initiation (evidence rating BII).

During PrEP, intervals of follow-up every 3 months are recommended to allow for HIV testing (evidence rating AlII) and STI screening (evidence rating Alia).

HCV serologic testing should be performed at least annually and more frequently in the case of elevated transaminase levels or in high-risk individuals (eg, people who inject drugs) (evidence rating Blia). PrEP prescription should not exceed 90 days without interval testing for HIV infection (evidence rating AlII); a visit 30 days after PrEP start is recommended for follow-up HIV testing, to assess adverse effects and support adherence (evidence rating BII).

Measurement of creatinine level should be performed at least every 6 months (evidence rating AlII) and more frequently for some patients (eg, those >50 years, taking hypertension or diabetes medications, or with glomerular filtration rates <90 mL/min) (evidence rating Blia).

Each PrEP visit should be used to assess and troubleshoot barriers to adherence to PrEP (evidence rating BII).

For confirmed HIV infection in the setting of PrEP use, a recommended initial antiretroviral regimen should be started, pending results of resistance testing (evidence rating AlII).

For individuals being treated with a course of 3-drug PEP for a recent exposure who are likely to be at risk of ongoing exposure, a seamless transition from PEP to PrEP is recommended (evidence rating CII).

If during PrEP treatment, exposure to HIV is known to occur, intensification of treatment with additional agent(s) is not recommended (evidence rating BII).

Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; MSM, men who have sex with men; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; STI, sexually transmitted infection; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

On-Demand or Event-Driven PrEP (“2-1-1”)

Percutaneous TDF/emtricitabine, known as on-demand or event-driven PrEP, is effective for HIV prevention among MSM and an alternative to daily PEP for MSM with infrequent sexual exposures (evidence rating Alia). The IPERGAY (Intervention Préventive de l’Exposition aux Risques avec et pour les Gays) study assessed...
on-demand PrEP with TDF/emtricitabine given as 2 doses with food 2 to 24 hours before sex, 1 dose 24 hours after the first (double) dose, and 1 dose 24 hours later (“2-1-1” dosing). For consecutive sexual contacts, men were instructed to take 1 pill per day until 2 days after the last sexual encounter. With each new sexual encounter, PrEP was to be initiated with a double dose, unless the last PrEP dose had occurred within 7 days, in which case only 1 preexposure dose was recommended. The IPERGAY and PROUD (Pre-exposure Option for Reducing HIV in the UK: Immediate or Deferred) trials (using daily TDF/emtricitabine) reduced risk by 86%. An analysis of MSM having infrequent sexual intercourse in the IPERGAY study and subsequent open-label extension studies found high levels of efficacy, including in a subgroup who took an average of 2 or 3 doses of TDF/emtricitabine per week. Clinical experience with on-demand PrEP confirmed efficacy of this dosing among MSM. The 2-1-1 regimen achieved target exposures of tenofovir diphosphate and emtricitabine triphosphate in colorectal tissue at the time of coitus in 81% and 98% of the population when administered 2 and 24 hours before coitus, respectively; target exposure was sustained for the next 10 days. If intercourse is planned, the first (double) dose of TDF/emtricitabine should be taken closer to the 24-hour precoital time than the 2-hour time (evidence rating CII).

Lack of data among heterosexual men and women, transgender men and women, and people who inject drugs precludes recommendation of the 2-1-1 regimen in these populations (evidence rating AII). The 2-1-1 regimen also is not recommended for patients with active HBV, because of risks of HBV reactivation and HBV resistance (evidence rating BIIa).

Regimen Choice and Laboratory Monitoring
TDF/emtricitabine is the recommended PrEP agent (evidence rating BII); TDF/tenofovir disoproxil fumarate, TAF/emtricitabine, or TDF alone are not recommended for PrEP at this time (evidence rating BII). TDF-based PrEP is not recommended for persons with creatinine clearance below 60 mL/min/1.73 m² (evidence rating AII). Glomerular dysfunction may occur with therapy, particularly in individuals older than 50 years. The dysfunction is usually reversible, and rechallenge with PrEP is often possible. Such patients should have more frequent creatinine clearance monitoring (evidence rating BIIa).

A combination HIV antigen-antibody assay should be performed within 7 days before initiation of TDF/emtricitabine PrEP to exclude HIV infection (evidence rating AII). An HIV RNA assay may be needed to exclude acute HIV infection in high-risk populations. A 1-month follow-up visit is recommended to assess adherence and tolerability and to ensure the absence of primary HIV infection (evidence rating BII). Subsequent follow-up is recommended every 3 months to allow for STI screening (urine, throat, anal, and vaginal tests) (evidence rating AII) and HIV testing (evidence rating AII). HCV serologic testing should be performed at least annually and more frequently in high-risk individuals (eg, people who inject drugs) or those with elevated transaminase levels (evidence rating BIIa). PrEP prescription should not exceed 90 days without interval testing for HIV infection (evidence rating AII).

Seroconversion in the Setting of PrEP
Diagnosing HIV infection in individuals taking PrEP can be challenging because PrEP can alter and delay antibody responses and decrease plasma HIV RNA levels. Any positive HIV screening test result in this setting should prompt immediate confirmatory testing with HIV RNA and genotype testing if confirmed. For suspected HIV infection or equivocal screening test results, PrEP should be stopped and other prevention methods used until HIV infection is confirmed or excluded. If HIV infection is confirmed or strongly suspected, fully suppressive ART should be administered as quickly as possible with a recommended regimen; resistance testing should be performed and treatment altered, as needed (evidence rating AII).

Resistance (typically with an M184V/I mutation) has been observed rarely, usually when PrEP with TDF/emtricitabine is initiated during undiagnosed acute HIV infection.

Additional Considerations
For high-risk individuals (including those who do not use safer sex or injection practices), the office visit to discuss PrEP is an opportunity to reduce risk. Same-day PrEP initiation is reasonable in some clinical scenarios. Asymptomatic individuals who are HIV-seronegative by rapid assay could initiate daily oral TDF/emtricitabine without awaiting results of the concomitant baseline testing of creatinine level, hepatitis B surface antigen level, STIs, and HIV by fourth-generation assay. Condom use should be encouraged for all genital contact to prevent STIs (evidence rating AII). TDF/emtricitabine PrEP is not fail-safe, and seroconversion despite excellent adherence has been reported in cases of high inoculum or viral resistance.

Unanticipated interruptions in PrEP delivery (eg, insurance coverage lapse, incarceration, and relocation) have been associated with seroconversions and should be avoided. For individuals being treated with a course of 3-drug PEP for a recent exposure, who are likely to be at risk of ongoing exposure, a seamless transition from PEP to PrEP is recommended (evidence rating CII). Given a negative result for a fourth-generation instrumented test (eg, combination HIV antigen-antibody test) at the conclusion of a 28-day PEP course, PrEP with daily TDF/emtricitabine may be initiated or resumed.

Future Directions
New treatments continue to be developed, most notably long-acting formulations of antiretrovirals for treatment and prevention. Injectable rilpivirine combined with cabotegravir was successful in phase 2 studies and is being evaluated in phase 3 clinical trials (NCT03299049). Also in development are implantable sustained-release platforms, nanoparticles, viral vector delivery, monoclonal antibodies, and other long-acting oral agents. Injectable and other long-acting preparations for PrEP, such as injectable cabotegravir and the dapivirine vaginal ring, are in clinical trials (NCT01617096). Open-label trials of the dapivirine vaginal ring demonstrated higher uptake and adherence than in the blinded trials, as well as HIV-1 incidence that was half the expected rate.

Broadly neutralizing antibodies (bNAbS) targeting conserved antigenic sites on the HIV-1 envelope trimer are being evaluated for therapy and prevention. Newer approaches to increase the potency, breadth, and half-life of bNAbS, evaluate different methods of bNAb administration, and assess the efficacy of combinations of bNAbS are being investigated.

HIV cure efforts focus on inducing HIV expression from latently infected cells, augmenting the immune system to clear infected cells...
Clinicians who care for patients with HIV have a major role in advocating for programs and their patients at the local, national, and international levels. Advocacy should go beyond access to ART and include access to mental health and substance abuse services as well as efforts to end policies such as HIV criminalization that impede the ability to provide evidence-based care and prevention services.

Role of the Funder/Sponsor: The IAS–USA determined the need to update recommendations, selected the panel members, and provided administrative support and oversight. The panel designed and conducted the work; collected, managed, analyzed, and interpreted the data; prepared, reviewed, and approved the manuscript; and submitted the manuscript for publication.

Additional Contributions: We thank Michelle Valderama, BS (IAS–USA), for administrative support and Haci Horváth, MA (University of California San Francisco), for conducting the PubMed and EMBASE literature searches.

REFERENCES


and in patients on CART. Medicine (Baltimore). 2016;95(42):e5094. doi:10.1097/MD.


104. Dombrowski JC, Galagan S, Ramchandani M, Dhanireddy S, Harrington RD, Golden MR. Improved outcomes with maximum, low-threshold HIV care (the “MAX CLINIC”). Presented at: 25th Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2018; Boston, MA.


107. Clemensi-Allen AA, Geng E, Christopoulous KA, et al. Degree of housing instability shows independent “dose-response” with HIV suppression. Presented at: 25th Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2018; Boston, MA.


Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

Meta-analysis of studies comparing single and multiple-tablet regimens, and adherence level in viral suppression by single-tablet regimens, was published in *The Lancet*. 2016;62(7):915-918. doi:10.1093/cid/civ1000


Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people was published in *JAMA*. 2017;318(18):2515-2524. doi:10.1001/jama.2017.00016


Cost-effective new strategies for prevention of drug-resistant HIV were published in *J Acquir Immune Defic Syndr*. 2013;64(4):382-391. doi:10.1097/QAI.0b013e318291ebdf

Clinical and epidemiologic characteristics of newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to pre-exposure prophylaxis (PrEP) was published in *Clin Infect Dis*. 2017;64(11):2237-2246. doi:10.1093/cid/cix185


Effectiveness results from the pilot phase of a pragmatic open-label randomised trial was published in *Lancet*. 2016;387(10013):53-60. doi:10.1016/S0140-6736(15)00356-2


prophylaxis during clinical care. Presented at: 2nd HIV Research for Prevention Conference (HIVR4P); October 17-21, 2016; Chicago, IL.


151. Nel A, van Niekerk N, Van Baelen B, Rosenberg Z. HIV incidence and adherence in DREAM: an open-label trial of dapivirine vaginal ring. Presented at: 25th Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2018; Boston, MA.


161. Borducchi E, Abbink P, Nikolova J, Lewis MG, Gelezunias R, Barouch D. PGT121 combined with GS-9620 delays viral rebound in SHIV-infected rhesus monkeys. Presented at: 25th Conference on Retroviruses and Opportunistic Infections (CROI); March 4-7, 2018; Boston, MA.